Context Therapeutics CNTX Institutional Ownership

Updated Oct 10, 2026

Context Therapeutics Inc. (NASDAQ:CNTX) was held by 80 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Collectively, these holders controlled 65.99% of Context Therapeutics' outstanding shares in Q2 2026, down from 78.03% in Q1 2026.
• Total holdings of Context Therapeutics shares fell 15.44% from Q1 2026, and the number of holders rose 110.53% from Q2 2025.
• Of these 80 holders, 56 added to their positions, 12 reduced their stakes and 12 left their positions unchanged.
• In total, institutional investors held 62.81Mn shares of Context Therapeutics at the end of Q2 2026, down 11.47Mn from the prior quarter and down 5.81Mn from a year earlier.
• As of June 30, 2026, Nextech Invest Ltd. held the largest stake in Context Therapeutics with 7.42Mn shares, or 7.79% of shares outstanding.
• Among holders that already owned Context Therapeutics, the biggest buyers in Q2 2026 were BlackRock, Inc. (+5.32Mn shares), Geode Capital Management, LLC (+1.23Mn shares), State Street Corp (+1.18Mn shares), Renaissance Technologies LLC (+858.4K shares) and Northern Trust Corp (+512.32K shares).
• Holders that trimmed the most shares of Context Therapeutics in Q2 2026 while keeping a position were MPM BioImpact LLC (-9.38Mn shares), Marshall Wace, LLP (-2.56Mn shares), Octagon Capital Advisors LP (-2.2Mn shares), Blue Owl Capital Holdings LP (-2.15Mn shares) and Millennium Management LLC (-1.28Mn shares).
• According to Business Quant data, the leading holders of CNTX for Q2 2026 were Nextech Invest Ltd. (7.42Mn shares), Deep Track Capital, LP (7.42Mn shares), Soleus Capital Management, L.P. (7.06Mn shares), BlackRock, Inc. (6.17Mn shares), Avidity Partners Management LP (5Mn shares), Franklin Templeton Inc (3.8Mn shares), Vanguard Capital Management LLC (3.43Mn shares), Octagon Capital Advisors LP (3.05Mn shares), Blue Owl Capital Holdings LP (2.93Mn shares) and TCG Crossover Management, LLC (2.68Mn shares).